SAN DIEGO, Mar. 28 (Korea Bizwire) — Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® [...]
Telesis Bio announces Q4 and full-year 2023 select preliminary financial results, highlighting strong BioXp kit sales, expanding gross margin and reduced expense SAN DIEGO, Feb. 26, 2024 (Korea Bizwire) – Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible and rapid automated [...]
New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in days SAN DIEGO, Nov. 03, 2023 (Korea Bizwire) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp® De novo Cloning and Amplification kit on the BioXp 3250 and BioXp [...]
New Kit expands suite of NGS Library Prep solutions on the BioXp® System Enabling Speed and Efficiency for Whole genome sequencing (WGS) applications with the Automated Molecular Biology Workstation SAN DIEGO, Sept. 28, 2023 (Korea Bizwire) – Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial [...]
SAN DIEGO, Aug. 29 (Korea Bizwire) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company’s financial planning and analysis, accounting, internal audit, tax, and treasury functions. [...]
SAN DIEGO, Aug. 3 (Korea Bizwire) – Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, August 10, 2023, [...]
SAN DIEGO, June 8 (Korea Bizwire) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time. [...]
SAN DIEGO, June 6 (Korea Bizwire) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their automated workflow solutions for streamlining discovery workflows in antibody and therapeutics development at Antibody Engineering and Therapeutics, Europe in Amsterdam, The Netherlands. In addition to the exhibition, [...]
SAN DIEGO, June 5 (Korea Bizwire) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the closing of its private placement of redeemable convertible preferred stock and warrants resulting in initial gross proceeds of $28.0 million to Telesis Bio. The warrants issued in [...]
SAN DIEGO, May 31 (Korea Bizwire) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds [...]